Xenon Pharmaceuticals Inc
XENE44.840USD
-0.170-0.38%
收盤 12/26, 16:00（美東）報價延遲15分鐘
3.46B總市值
虧損本益比TTM
關於 Xenon Pharmaceuticals Inc 公司
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
Xenon Pharmaceuticals Inc簡介
公司代碼XENE
公司名稱Xenon Pharmaceuticals Inc
上市日期Oct 17, 2014
CEOMortimer (Ian C)
員工數量316
證券類型Ordinary Share
年結日Oct 17
公司地址3650 Gilmore Way
城市VANCOUVER
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Canada
郵編V5G 4W8
電話16044843300
網址https://www.xenon-pharma.com/
公司代碼XENE
上市日期Oct 17, 2014
CEOMortimer (Ian C)
Xenon Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Principal Operating Officer, Director
President, Chief Executive Officer, Principal Operating Officer, Director
20.30K
-55.39%
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Mr. Thomas J. (Tucker) Kelly, J.D.
Mr. Thomas J. (Tucker) Kelly, J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
--
--
Dr. Gillian M. Cannon, Ph.D.
Dr. Gillian M. Cannon, Ph.D.
Independent Director
Independent Director
--
--
Mr. Justin Gover
Mr. Justin Gover
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Principal Operating Officer, Director
President, Chief Executive Officer, Principal Operating Officer, Director
20.30K
-55.39%
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Mr. Thomas J. (Tucker) Kelly, J.D.
Mr. Thomas J. (Tucker) Kelly, J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明細
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
由於公司未披露，未能獲取相關數據
地區USD
名稱
營收
佔比
Canada
0.00
0.00%
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
8.09%
Avoro Capital Advisors LLC
6.99%
Driehaus Capital Management, LLC
5.40%
BlackRock Institutional Trust Company, N.A.
5.25%
Janus Henderson Investors
5.10%
其他
69.17%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
8.09%
Avoro Capital Advisors LLC
6.99%
Driehaus Capital Management, LLC
5.40%
BlackRock Institutional Trust Company, N.A.
5.25%
Janus Henderson Investors
5.10%
其他
69.17%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
48.11%
Investment Advisor
33.86%
Hedge Fund
25.98%
Research Firm
1.49%
Private Equity
1.01%
Sovereign Wealth Fund
0.82%
Pension Fund
0.75%
Bank and Trust
0.40%
Individual Investor
0.11%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
446
85.67M
110.86%
-494.45K
2025Q2
418
85.39M
111.27%
+856.94K
2025Q1
434
79.94M
104.19%
-5.23M
2024Q4
434
79.81M
104.31%
-4.80M
2024Q3
425
77.49M
102.39%
-3.82M
2024Q2
431
76.92M
102.03%
-4.12M
2024Q1
421
76.68M
101.81%
-2.76M
2023Q4
404
75.13M
102.42%
+7.65M
2023Q3
386
64.60M
99.41%
-3.93M
2023Q2
377
64.25M
101.09%
-4.03M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
6.40M
8.3%
+244.00K
+3.96%
Jun 30, 2025
Avoro Capital Advisors LLC
5.40M
7%
-341.67K
-5.95%
Jun 30, 2025
Driehaus Capital Management, LLC
4.34M
5.62%
-249.21K
-5.44%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.12M
5.34%
+3.47M
+534.85%
Jun 30, 2025
Janus Henderson Investors
3.58M
4.64%
+252.64K
+7.60%
Jun 30, 2025
Wellington Management Company, LLP
2.17M
2.82%
-1.61M
-42.61%
Jun 30, 2025
Braidwell LP
3.61M
4.68%
+895.15K
+33.03%
Jun 30, 2025
Capital International Investors
3.18M
4.13%
+92.82K
+3.01%
Jun 30, 2025
Commodore Capital LP
3.02M
3.92%
+700.00K
+30.11%
Jun 30, 2025
Fidelity Institutional Asset Management
2.48M
3.22%
+352.87K
+16.57%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Neuroscience and Healthcare ETF
4.41%
ALPS Medical Breakthroughs ETF
1.35%
Goldman Sachs Future Health Care Equity ETF
1.13%
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
First Trust Multi-Manager Small Cap Opportunities ETF
0.8%
JPMorgan Fundamental Data Science Small Core ETF
0.57%
JPMorgan Healthcare Leaders ETF
0.53%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.45%
ProShares Ultra Nasdaq Biotechnology
0.42%
Invesco Nasdaq Biotechnology ETF
0.32%
查看更多
iShares Neuroscience and Healthcare ETF
佔比4.41%
ALPS Medical Breakthroughs ETF
佔比1.35%
Goldman Sachs Future Health Care Equity ETF
佔比1.13%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.87%
First Trust Multi-Manager Small Cap Opportunities ETF
佔比0.8%
JPMorgan Fundamental Data Science Small Core ETF
佔比0.57%
JPMorgan Healthcare Leaders ETF
佔比0.53%
iShares MSCI USA Small-Cap Min Vol Factor ETF
佔比0.45%
ProShares Ultra Nasdaq Biotechnology
佔比0.42%
Invesco Nasdaq Biotechnology ETF
佔比0.32%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Xenon Pharmaceuticals Inc的前五大股東是誰？
Xenon Pharmaceuticals Inc的前五大股東如下：
Fidelity Management & Research Company LLC持有股份：6.40M佔總股份比例：8.30%。
Avoro Capital Advisors LLC持有股份：5.40M佔總股份比例：7.00%。
Driehaus Capital Management, LLC持有股份：4.34M佔總股份比例：5.62%。
BlackRock Institutional Trust Company, N.A.持有股份：4.12M佔總股份比例：5.34%。
Janus Henderson Investors持有股份：3.58M佔總股份比例：4.64%。
Fidelity Management & Research Company LLC持有股份：6.40M佔總股份比例：8.30%。
Avoro Capital Advisors LLC持有股份：5.40M佔總股份比例：7.00%。
Driehaus Capital Management, LLC持有股份：4.34M佔總股份比例：5.62%。
BlackRock Institutional Trust Company, N.A.持有股份：4.12M佔總股份比例：5.34%。
Janus Henderson Investors持有股份：3.58M佔總股份比例：4.64%。
Xenon Pharmaceuticals Inc的前三大股東類型是什麼？
Xenon Pharmaceuticals Inc 的前三大股東類型分別是：
Fidelity Management & Research Company LLC
Avoro Capital Advisors LLC
Driehaus Capital Management, LLC
Fidelity Management & Research Company LLC
Avoro Capital Advisors LLC
Driehaus Capital Management, LLC
有多少機構持有Xenon Pharmaceuticals Inc(XENE)的股份？
截至2025Q3，共有446家機構持有Xenon Pharmaceuticals Inc的股份，合計持有的股份價值約為85.67M，占公司總股份的110.86% 。與2025Q2相比，機構持股有所增加，增幅為-0.41%。
哪個業務部門對Xenon Pharmaceuticals Inc的收入貢獻最大？
在FY2025Q2，--業務部門對Xenon Pharmaceuticals Inc的收入貢獻最大，創收--，占總收入的--% 。
